Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Breast Neoplasms | 10 | 2024 | 150 | 4.650 |
Why?
|
Breast Neoplasms | 36 | 2025 | 21162 | 2.210 |
Why?
|
BRCA2 Protein | 9 | 2024 | 802 | 1.580 |
Why?
|
Receptor, erbB-2 | 11 | 2025 | 2598 | 1.490 |
Why?
|
BRCA1 Protein | 9 | 2024 | 1155 | 1.400 |
Why?
|
Paclitaxel | 3 | 2024 | 1728 | 0.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2025 | 11876 | 0.940 |
Why?
|
Neoadjuvant Therapy | 13 | 2024 | 2902 | 0.860 |
Why?
|
Pyrazoles | 2 | 2024 | 2030 | 0.770 |
Why?
|
Nitriles | 2 | 2024 | 981 | 0.740 |
Why?
|
Ovarian Neoplasms | 4 | 2023 | 4903 | 0.700 |
Why?
|
Platinum | 1 | 2021 | 219 | 0.660 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13644 | 0.640 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2019 | 2143 | 0.550 |
Why?
|
Anthracyclines | 3 | 2020 | 286 | 0.520 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2017 | 329 | 0.520 |
Why?
|
Neutropenia | 1 | 2021 | 895 | 0.510 |
Why?
|
Camptothecin | 3 | 2024 | 599 | 0.490 |
Why?
|
Immunoconjugates | 4 | 2024 | 976 | 0.490 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 1514 | 0.480 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2025 | 352 | 0.470 |
Why?
|
Pyrimidines | 2 | 2024 | 3043 | 0.460 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 926 | 0.450 |
Why?
|
Medically Underserved Area | 1 | 2015 | 268 | 0.430 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1241 | 0.420 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2823 | 0.410 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 591 | 0.400 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 753 | 0.380 |
Why?
|
Female | 52 | 2025 | 396532 | 0.350 |
Why?
|
Vulnerable Populations | 1 | 2015 | 718 | 0.340 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2025 | 562 | 0.330 |
Why?
|
Troponin I | 2 | 2017 | 659 | 0.330 |
Why?
|
Genetic Testing | 4 | 2024 | 3591 | 0.330 |
Why?
|
Troponin T | 2 | 2017 | 786 | 0.310 |
Why?
|
Patient Selection | 3 | 2021 | 4252 | 0.310 |
Why?
|
Aminopyridines | 2 | 2025 | 577 | 0.290 |
Why?
|
Humans | 62 | 2025 | 766812 | 0.290 |
Why?
|
Maytansine | 2 | 2019 | 88 | 0.290 |
Why?
|
Urban Population | 1 | 2015 | 2040 | 0.280 |
Why?
|
Piperazines | 3 | 2025 | 2547 | 0.270 |
Why?
|
Ovariectomy | 2 | 2020 | 612 | 0.260 |
Why?
|
Population Surveillance | 1 | 2015 | 2594 | 0.240 |
Why?
|
Aromatase Inhibitors | 2 | 2025 | 519 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 2 | 2025 | 5690 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9407 | 0.210 |
Why?
|
Neoplasms | 4 | 2024 | 22350 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9101 | 0.200 |
Why?
|
Lymphoma | 1 | 2011 | 1899 | 0.200 |
Why?
|
Receptors, Estrogen | 4 | 2025 | 2252 | 0.200 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2057 | 0.190 |
Why?
|
Mutation | 7 | 2022 | 30214 | 0.190 |
Why?
|
Maximum Tolerated Dose | 2 | 2024 | 896 | 0.190 |
Why?
|
Weight Gain | 1 | 2011 | 2356 | 0.190 |
Why?
|
Omeprazole | 1 | 2021 | 106 | 0.180 |
Why?
|
Survivors | 1 | 2011 | 2379 | 0.180 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 428 | 0.180 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11218 | 0.180 |
Why?
|
Phthalazines | 1 | 2023 | 397 | 0.180 |
Why?
|
Pyridines | 3 | 2025 | 2888 | 0.170 |
Why?
|
Middle Aged | 25 | 2025 | 223267 | 0.170 |
Why?
|
Purines | 2 | 2025 | 615 | 0.160 |
Why?
|
Urogenital System | 1 | 2019 | 88 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 18076 | 0.160 |
Why?
|
Lisinopril | 1 | 2019 | 60 | 0.160 |
Why?
|
Prognosis | 4 | 2023 | 29959 | 0.160 |
Why?
|
Treatment Outcome | 9 | 2024 | 65286 | 0.160 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 581 | 0.150 |
Why?
|
Germ-Line Mutation | 2 | 2024 | 1886 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 646 | 0.150 |
Why?
|
Carboplatin | 1 | 2021 | 790 | 0.150 |
Why?
|
Adult | 20 | 2025 | 223305 | 0.150 |
Why?
|
Benzimidazoles | 2 | 2025 | 862 | 0.140 |
Why?
|
Cardiac Imaging Techniques | 1 | 2020 | 280 | 0.140 |
Why?
|
Aged | 15 | 2025 | 171344 | 0.140 |
Why?
|
Brain | 1 | 2024 | 27158 | 0.140 |
Why?
|
Lymphedema | 1 | 2023 | 526 | 0.140 |
Why?
|
Genetic Counseling | 2 | 2023 | 634 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 678 | 0.130 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.130 |
Why?
|
Retrospective Studies | 8 | 2025 | 81657 | 0.130 |
Why?
|
District of Columbia | 1 | 2015 | 159 | 0.120 |
Why?
|
Central Nervous System | 1 | 2022 | 1345 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 2021 | 1612 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1062 | 0.120 |
Why?
|
Mastectomy | 1 | 2023 | 1861 | 0.120 |
Why?
|
Genetic Heterogeneity | 1 | 2018 | 735 | 0.120 |
Why?
|
Jews | 1 | 2016 | 359 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 2045 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4892 | 0.110 |
Why?
|
Breast | 1 | 2023 | 1972 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1381 | 0.110 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2631 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2024 | 3226 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 949 | 0.110 |
Why?
|
RNA | 1 | 2023 | 2715 | 0.110 |
Why?
|
Estrogens | 1 | 2019 | 1528 | 0.100 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59548 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4056 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2912 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10745 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5330 | 0.090 |
Why?
|
Time Factors | 5 | 2021 | 40149 | 0.090 |
Why?
|
Radiation Injuries | 1 | 2019 | 1195 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2023 | 3552 | 0.090 |
Why?
|
Obesity | 2 | 2023 | 13090 | 0.090 |
Why?
|
Carrier Proteins | 1 | 2024 | 4926 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6853 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3942 | 0.090 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3934 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2662 | 0.080 |
Why?
|
Germ Cells | 2 | 2024 | 644 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7438 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1120 | 0.080 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.080 |
Why?
|
Young Adult | 6 | 2020 | 59939 | 0.080 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1012 | 0.070 |
Why?
|
Heart Diseases | 1 | 2020 | 2817 | 0.070 |
Why?
|
DNA Repair | 1 | 2016 | 2050 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8728 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 820 | 0.060 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 1998 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5038 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21527 | 0.060 |
Why?
|
Heart Failure | 1 | 2008 | 11879 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9602 | 0.060 |
Why?
|
Neuropilin-1 | 1 | 2024 | 90 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4425 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3600 | 0.050 |
Why?
|
Registries | 2 | 2020 | 8352 | 0.050 |
Why?
|
Pamphlets | 1 | 2023 | 71 | 0.050 |
Why?
|
Risk Assessment | 4 | 2024 | 24299 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18397 | 0.050 |
Why?
|
Risk Factors | 6 | 2023 | 74889 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 630 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 297 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9528 | 0.050 |
Why?
|
Axilla | 1 | 2023 | 622 | 0.040 |
Why?
|
Animals | 4 | 2024 | 168939 | 0.040 |
Why?
|
Body Weight | 1 | 2011 | 4626 | 0.040 |
Why?
|
Prospective Studies | 3 | 2023 | 54872 | 0.040 |
Why?
|
Genomics | 1 | 2016 | 5922 | 0.040 |
Why?
|
Stroke Volume | 3 | 2021 | 5618 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2025 | 1159 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3692 | 0.040 |
Why?
|
Telephone | 1 | 2023 | 629 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15835 | 0.040 |
Why?
|
Administration, Intravaginal | 1 | 2019 | 149 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
United States | 4 | 2025 | 72945 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 734 | 0.040 |
Why?
|
Comprehension | 1 | 2024 | 638 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 466 | 0.040 |
Why?
|
Sex Factors | 1 | 2011 | 10619 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3667 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2023 | 1267 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 456 | 0.030 |
Why?
|
Logistic Models | 1 | 2011 | 13276 | 0.030 |
Why?
|
Quality of Life | 2 | 2022 | 13476 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2024 | 1349 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2022 | 1089 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1317 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3274 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1902 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15425 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2334 | 0.030 |
Why?
|
Atrophy | 1 | 2019 | 1631 | 0.030 |
Why?
|
Body Mass Index | 1 | 2011 | 13050 | 0.030 |
Why?
|
Gynecology | 1 | 2019 | 534 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14653 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15652 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 88902 | 0.030 |
Why?
|
Male | 4 | 2024 | 364154 | 0.020 |
Why?
|
Radiotherapy | 1 | 2019 | 1497 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2019 | 2425 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 3138 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2469 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2801 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4114 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2303 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2229 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2591 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10101 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4747 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17089 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10384 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6514 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1880 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2190 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9661 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 8065 | 0.010 |
Why?
|
Recurrence | 1 | 2017 | 8507 | 0.010 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39312 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26309 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81898 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41706 | 0.010 |
Why?
|
Concepts
(197)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(59)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_